Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites.
D000328:Adult; D000342:Affective Symptoms / Q000134:cerebrospinal fluid / Q000188:drug therapy; D000368:Aged; D001679:Biogenic Amines / Q000134:cerebrospinal fluid*; D001714:Bipolar Disorder / Q000134:cerebrospinal fluid / Q000188:drug therapy; D003863:Depression / Q000134:cerebrospinal fluid / Q000188:drug therapy; D004569:Electroencephalography; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011339:Probenecid / Q000134:cerebrospinal fluid; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000134:cerebrospinal fluid / Q000188:drug therapy; D014364:Tryptophan / Q000134:cerebrospinal fluid
D001679:Biogenic Amines; D006897:Hydroxyindoleacetic Acid; D014364:Tryptophan; D008094:Lithium; D011339:Probenecid; D006719:Homovanillic Acid